RT Book, Section
A1 Francis, Prudence A.
A2 Kuerer, Henry M.
SR Print(0)
ID 6417023
T1 Chapter 86. Endocrine Therapy
T2 Kuerer's Breast Surgical Oncology
YR 2010
FD 2010
PB The McGraw-Hill Companies
PP New York, NY
SN 978-0-07-160178-8
LK accesssurgery.mhmedical.com/content.aspx?aid=6417023
RD 2024/10/15
AB Among  postoperative  therapies  for  early  breast  cancer,  endocrine  therapy  is  responsible  for  the  greatest  reduction  in  the  risk  of  recurrence  and  death.  Following  resection  of  hormone  receptor–positive  breast  cancer,  adjuvant  endocrine  therapy  reduces  the  risk  of  local  recurrence,  distant  metastasis,  and  contralateral  breast  cancer.  Currently  new  medical  oncology  treatments  described  as  targeted  therapies  are  improving  outcomes  in  a  variety  of  malignancies.  Tamoxifen  treatment  for  breast  cancer  represents  the  first  successful  application  of  a  targeted  therapy,  where  the  drug  targets  the  estrogen  receptor  (ER)  on  any  residual  tumor  cells.  Tamoxifen  is  described  as  a  selective  estrogen  receptor  modulator  (SERM)  because  of  its  varying  effects  in  different  tissues,  where  it  may  act  as  an  antagonist  (eg,  breast)  or  an  agonist  (eg,  uterus).